Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: The Health 2000 Survey

Clinical and Experimental Immunology

Volumn 164, Issue 2, 2011, Pages 211-217

  Jylhava J ^a   Haarala, A ^a   Kahonen M ^a,b   Lehtimaki T ^a,b   Jula, A ^c   Moilanen, L ^d   Kesaniemi Y A ^e   Nieminen, M S ^f   Hurme, M ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Acute phase proteins; Atherosclerosis; Inflammation inflammatory mediators including eicosanoids

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOLEAMINE 2,3 DIOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; FINLAND; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS; SERUM AMYLOID P-COMPONENT;

EID: 79953779537     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04354.x     Document Type: Article

References (33)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-26.
2. Peri G, Introna M, Corradi D etal. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102:636-41.
3. Latini R, Maggioni AP, Peri G etal. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110:2349-54.
4. Suzuki S, Takeishi Y, Niizeki T etal. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155:75-81.
5. Libby P, Willerson JT, Braunwald E. C-reactive protein and coronary heart disease. N Engl J Med 2004; 351:295-8; author reply 295-298.
6. Kotooka N, Inoue T, Aoki S etal. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008; 130:19-22.
7. Matsui S, Ishii J, Kitagawa F etal. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010; 210:220-5.
8. Bottazzi B, Garlanda C, Cotena A etal. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009; 227:9-18.
9. Jaillon S, Peri G, Delneste Y etal. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204:793-804.
10. Bottazzi B, Vouret-Craviari V, Bastone A etal. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272:32817-23.
11. Salio M, Chimenti S, De Angelis N etal. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117:1055-64.
12. Norata GD, Marchesi P, Pulakazhi Venu VK etal. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009; 120:699-708.
13. Rolph MS, Zimmer S, Bottazzi B etal. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22:e10-14.
14. Savchenko A, Imamura M, Ohashi R etal. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215:48-55.
15. Aromaa AKS. Health and functional capacity in Finland. Baseline results of the Health 2000 Health examination Survey. Publications of the National Public Health Institute 2004; B12/2004.
16. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366:1059-62.
17. Graham I, Atar D, Borch-Johnsen K etal. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375-414.
18. Matthews DR, Hosker JP, Rudenski AS etal. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-19.
19. Sipila K, Moilanen L, Nieminen T etal. Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey. Atherosclerosis 2009; 204:276-81.
20. Niinisalo P, Raitala A, Pertovaara M etal. Indoleamine 2, 3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 2008; 68:767-70.
21. Niiranen T, Jula A, Kantola I etal. Home-measured blood pressure is more strongly associated with atherosclerosis than clinic blood pressure: the Finn-HOME Study. J Hypertens 2007; 25:1225-31.
22. Zanetti M, Bosutti A, Ferreira C etal. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009; 9:243-8.
23. Yamasaki K, Kurimura M, Kasai T etal. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 2009; 47:471-7.
24. Hollan I, Bottazzi B, Cuccovillo I etal. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res (Hoboken) 2010; 62:378-85.
25. Jenny NS, Arnold AM, Kuller LH etal. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009; 29:594-9.
26. Alberti L, Gilardini L, Zulian A etal. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009; 202:455-60.
27. Bosutti A, Grassi G, Zanetti M etal. Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients. Clin Exp Med 2007; 7:16-23.
28. Ohbayashi H, Miyazawa C, Miyamoto K etal. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 2009; 16:490-500.
29. Norata GD, Marchesi P, Pirillo A etal. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28:925-31.
30. Deban L, Russo RC, Sironi M etal. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11:328-34.
31. Xu H, Zhang GX, Ciric B, Rostami A. IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett 2008; 121:1-6.
32. Yano Y, Matsuda S, Hatakeyama K etal. Plasma pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci 2010; 65:547-52.
33. Yilmaz MI, Axelsson J, Sonmez A etal. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009; 4:535-41.